Kako, Shinichi http://orcid.org/0000-0002-2635-3395
Hayakawa, Fumihiko
Imai, Kiyotoshi
Tanaka, Junji
Mizuta, Shuichi
Nishiwaki, Satoshi
Kanamori, Heiwa
Mukae, Junichi
Ozawa, Yukiyasu
Kondo, Tadakazu
Fukuda, Takahiro
Ichinohe, Tatsuo
Ota, Shuichi
Tanaka, Yoshinori
Murayama, Tohru
Kurahashi, Shingo
Sakura, Toru
Usui, Noriko
Ohtake, Shigeki
Kiyoi, Hitoshi
Matsumura, Itaru
Miyazaki, Yasushi
Atsuta, Yoshiko
Funding for this research was provided by:
japan agency for medical research and development (JP19ck0106331, 19ek0510023h0002)
Article History
Received: 11 June 2021
Revised: 20 July 2021
Accepted: 21 July 2021
First Online: 30 July 2021
Declarations
:
: Ota S has received honoraria from Novartis Pharma K.K. Usui N has received consulting fees from Cmic Co., Ltd., AbbVie GK, Nippon Shinyaku Co., Ltd., and Daiichi Sankyo Co., Ltd. and honoraria from Celgene Co., Ltd., SymBio Pharmaceuticals, Pfizer Japan Inc., Bristol-Myers Squibb, MundiPharma K.K., IQVIA Services Japan K.K., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Zenyaku Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Kiyoi H has received research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., Perseus Proteomics Inc. and Celgene Corporation., consulting fees from Astellas Pharma Inc., Amgen Astellas BioPharma K.K., and Daiichi Sankyo Co., Ltd., and honoraria from Bristol-Myers Squibb, Astellas Pharma Inc., and Novartis Pharma K.K. Matsumura I has received research funding from Chugai Pharmaceutical Co., Ltd., Novartis Pharma KK, AbbVie GK., Takeda Pharmaceutical Company Limited., Pfizer Japan Inc., Eisai Co., Ltd., and MSD K.K. and honoraria from Novartis Pharma KK, Bristol-Myers Squibb Company, Pfizer Japan Inc., DAIICHI SANKYO COMPANY, LIMITED., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., and Amgen Astellas BioPharma K.K. Matsumura I also belonged to a laboratory supported, in part, by ONO PHARMACEUTICAL CO., LTD., Takeda Pharmaceutical Company Limited., Chugai Pharmaceutical Co., Ltd., NIPPON SHINYAKU CO.,LTD., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., AbbVie GK., ASAHI KASEI PHARMA CORPORATION, Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., Sanofi K.K., Pfizer Japan Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma KK, and Astellas Pharma Inc.